Topical Treatment with Cord Blood Serum in Glaucoma Patients: A Preliminary Report
Purpose. To report data which happened to be observed in two glaucoma patients treated with Cord Blood Serum (CBS) eye drops. Design. A case report and retrospective data analysis. Methods. CBS topical eye drops, characterized in advance for growth factors (GFs) content, were administered for two months with the aim to relieve their subjective symptoms, in two patients who had referred ocular surface discomfort, although in absence of any sign of keratopathy. As patients were also affected by advanced glaucoma at risk of vision loss and under treatment with hypotensive drugs, they had been also monitored over the same period with IOP controls and visual field tests in our unit. Results. During subsequent visits, data from Mean Deviation and Pattern Standard Deviation in the visual fields were retrospectively collected and compared with before and after treatment with CBS, and an amelioration was observed. Conclusions. CBS contains a combination of GFs, which potentially exert a neuroprotective action and elect CBS as an interesting natural source to be delivered in neurodegenerative ocular disorders. The incidentally observed amelioration in these two patients deserves further investigation in this respect..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2018 |
|---|---|
| Enthalten in: |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Emilio Campos [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1155/2018/2381296 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ033219605 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ033219605 | ||
| 003 | DE-627 | ||
| 005 | 20230307174931.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1155/2018/2381296 |2 doi | |
| 035 | |a (DE-627)DOAJ033219605 | ||
| 035 | |a (DE-599)DOAJ72ae0f38fd024e4fa47c28c2f870ea0c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RE1-994 | |
| 100 | 0 | |a Emilio Campos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Topical Treatment with Cord Blood Serum in Glaucoma Patients: A Preliminary Report |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Purpose. To report data which happened to be observed in two glaucoma patients treated with Cord Blood Serum (CBS) eye drops. Design. A case report and retrospective data analysis. Methods. CBS topical eye drops, characterized in advance for growth factors (GFs) content, were administered for two months with the aim to relieve their subjective symptoms, in two patients who had referred ocular surface discomfort, although in absence of any sign of keratopathy. As patients were also affected by advanced glaucoma at risk of vision loss and under treatment with hypotensive drugs, they had been also monitored over the same period with IOP controls and visual field tests in our unit. Results. During subsequent visits, data from Mean Deviation and Pattern Standard Deviation in the visual fields were retrospectively collected and compared with before and after treatment with CBS, and an amelioration was observed. Conclusions. CBS contains a combination of GFs, which potentially exert a neuroprotective action and elect CBS as an interesting natural source to be delivered in neurodegenerative ocular disorders. The incidentally observed amelioration in these two patients deserves further investigation in this respect. | ||
| 653 | 0 | |a Ophthalmology | |
| 700 | 0 | |a Piera Versura |e verfasserin |4 aut | |
| 700 | 0 | |a Giuseppe Giannaccare |e verfasserin |4 aut | |
| 700 | 0 | |a Adriana Terzi |e verfasserin |4 aut | |
| 700 | 0 | |a Silvia Bisti |e verfasserin |4 aut | |
| 700 | 0 | |a Stefano Di Marco |e verfasserin |4 aut | |
| 700 | 0 | |a Marina Buzzi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Case Reports in Ophthalmological Medicine |d Hindawi Limited, 2011 |g (2018) |w (DE-627)DOAJ000114766 |x 20906730 |7 nnns |
| 773 | 1 | 8 | |g year:2018 |
| 856 | 4 | 0 | |u https://doi.org/10.1155/2018/2381296 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/72ae0f38fd024e4fa47c28c2f870ea0c |z kostenfrei |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1155/2018/2381296 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2090-6722 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2090-6730 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2018 | ||